RWJ-67657

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameRWJ-67657
Drug Alias NameRWJ-67657
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionP38 mitogen-activated protein kinase inhibitors
TargetsP38 mitogen-activated protein kinase
Therapy Area/IndicationsInflammatory Bowel DiseasesArthritis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesJohnson & Johnson Innovative Medicine
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesJohnson & Johnson Innovative Medicine
Active IndicationsN/A
Inactive IndicationsInflammatory Bowel DiseasesArthritis

Other Information

ATC CodeN/A
Related LinksN/A